Session-aware quotes · provider delays vary · Not financial advice
BullishMEDIUM severityTech & AI25d ago

Bristol-Myers raises 2026 guidance as Eliquis growth seen at 20%-25% and milvexian AFib readout shifts to Q1 2027

Reported by Seeking Alpha · seekingalpha.com · July 30, 2026

$BMY
Bullish read

What the tape says

What to watch: Bristol-Myers Squibb Co. (BMY) raised guidance toward 20% — confirm the raise reflects durable demand, not a one-time item.

Change
20%
Change
-25%

Market reaction today: $BMY +0.40%

Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish Seeking Alpha's reporting.

Your read

Discussion

No one has weighed in yet. Start the discussion on this story.

More coverage on these names

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.